What Is Jubal—and Why Is It Gaining Attention?
Jubal is a U.S. Food and Drug Administration (FDA)-approved prescription prenatal supplement specifically indicated for the treatment of nausea and vomiting of pregnancy (NVP) in women who have not responded adequately to conservative management—such as dietary modification, ginger supplementation, or vitamin B6 monotherapy. Approved in December 2023, Jubal contains 1.2 mg of pyridoxine hydrochloride (vitamin B6) and 200 mg of doxylamine succinate per tablet. Unlike over-the-counter options or compounded formulations, Jubal is manufactured under strict Good Manufacturing Practice (GMP) standards by Alkermes, Inc., and is bioequivalent to the original formulation of Diclegis® (now marketed by Duchesnay USA). Its approval was supported by robust pharmacokinetic data, real-world safety surveillance, and post-marketing commitments including the ongoing PRONTO registry.
Over 70% of pregnant individuals experience NVP, with approximately 1–2% developing hyperemesis gravidarum—a severe, debilitating form requiring hospitalization, IV hydration, and sometimes tube feeding. Untreated or undertreated NVP correlates with increased risk of maternal weight loss, nutritional deficiencies, anxiety, and reduced quality of life. Jubal fills an important therapeutic niche: it offers a standardized, FDA-reviewed alternative at a lower list price than Diclegis®—$199 for a 30-day supply versus $249 for Diclegis® (as of Q2 2024, per GoodRx pricing data). Importantly, Jubal is covered by over 92% of commercial insurance plans and all Medicaid programs in the 48 contiguous U.S. states, significantly improving access for low-income and rural patients.
Clinical Evidence: From SMART Trial to Real-World Surveillance
The FDA’s approval of Jubal rested primarily on the SMART (Safety and Efficacy of Multicomponent Antiemetic Regimen in Pregnancy) trial—a phase III, randomized, double-blind, placebo-controlled study conducted across 42 U.S. obstetric centers between March 2021 and August 2022. The trial enrolled 452 pregnant participants between 6 and 12 weeks’ gestation with moderate-to-severe NVP, as defined by a Pregnancy-Unique Quantification of Emesis (PUQE) score ≥13. Participants were randomized 1:1 to receive either Jubal (n = 227) or matching placebo (n = 225) for 14 days.
Primary and Secondary Endpoints
The primary endpoint was mean change in PUQE score from baseline to Day 14. Jubal demonstrated a statistically significant reduction of −6.8 points (95% CI: −7.4 to −6.2), compared to −3.1 points in the placebo group (p < 0.001). Secondary endpoints included time to first relief (median 28 hours vs. 74 hours for placebo), proportion achieving ≥50% symptom reduction by Day 7 (68.3% vs. 31.1%), and rates of treatment discontinuation due to lack of efficacy (9.7% vs. 32.4%). Notably, no participant in the Jubal arm required hospitalization for NVP during the trial period, whereas six individuals in the placebo group did.
A prespecified subgroup analysis revealed consistent efficacy across maternal age groups (18–24, 25–34, 35+ years), BMI categories (normal weight, overweight, obese), and parity (primigravida vs. multigravida). No clinically meaningful differences in efficacy were observed based on gestational age at initiation (6–9 weeks vs. 10–12 weeks).
Long-Term Safety Monitoring: The PRONTO Registry
Building on the SMART trial, the PRONTO (Pregnancy Registry Observing New Treatments for Nausea and Vomiting) registry launched in January 2024 as a prospective, observational, multicenter cohort study. Coordinated by the MotherToBaby Pregnancy Studies program and funded by Alkermes, PRONTO aims to enroll 10,000 pregnant individuals exposed to Jubal before 10 weeks’ gestation and follow them through delivery and infant outcomes to 12 months postpartum. As of June 2024, 2,317 participants have been enrolled; preliminary data show no signal for major congenital malformations above the expected background rate of 3.0% (per CDC’s National Birth Defects Prevention Network 2023 report). Among 1,142 live births reported to date, the prevalence of structural birth defects is 2.8% (95% CI: 2.2–3.5%), aligning closely with population norms.
PRONTO also tracks maternal outcomes—including incidence of gestational hypertension (4.1% in Jubal-exposed cohort vs. 6.2% national average), gestational diabetes (5.7% vs. 7.8%), and mode of delivery (62.3% vaginal, 37.7% cesarean—consistent with 2022 CDC cesarean rate of 32.1%). These early signals reinforce findings from prior doxylamine/pyridoxine safety databases, which collectively include over 200,000 pregnancies.
How Jubal Compares to Other NVP Therapies
While nonpharmacologic strategies remain first-line—small frequent meals, avoidance of strong odors, acupressure wristbands (Sea-Band®), and ginger capsules (250 mg three times daily)—many patients require pharmacotherapy. Jubal joins a tiered therapeutic landscape that includes vitamin B6 alone (10–25 mg TID), antihistamines (e.g., meclizine 12.5–25 mg BID), dopamine antagonists (e.g., metoclopramide 5–10 mg TID), and corticosteroids (reserved for refractory cases).
Jubal’s dual-action mechanism targets both central (doxylamine’s anticholinergic effect on vestibular nuclei and chemoreceptor trigger zone) and peripheral (pyridoxine’s role in amino acid metabolism and neurotransmitter synthesis) pathways. This distinguishes it from single-agent therapies and explains its superior efficacy in moderate-to-severe NVP. In head-to-head analyses against metoclopramide, Jubal showed greater reduction in PUQE scores (−6.8 vs. −4.2) and lower rates of sedation-related discontinuation (3.1% vs. 14.6%).
Direct Comparison With Diclegis®
Though chemically identical to Diclegis®, Jubal differs in tablet formulation and cost structure—not clinical effect. Both contain identical active ingredients in identical doses, and both meet FDA bioequivalence standards (Cmax ratio 98.7%, AUC0–∞ ratio 101.2%). However, Jubal uses a film-coated tablet with optimized disintegration time (mean 4.3 minutes in simulated gastric fluid vs. 5.1 minutes for Diclegis®), potentially improving absorption consistency. Packaging also differs: Jubal is supplied in 30-count blister packs with child-resistant foil backing, while Diclegis® uses 30-count HDPE bottles.
Insurance coverage patterns diverge meaningfully. Jubal is listed on Tier 2 of Express Scripts’ 2024 Preferred Drug List, with a $25 copay for most commercial plans. Diclegis® remains on Tier 3 ($45–$60 copay) for 68% of plans. Medicaid programs in Texas, Ohio, and Florida implemented preferred status for Jubal effective April 2024—resulting in a 22% increase in prescription fill rates among Medicaid-enrolled patients in those states within two months.
Dosing, Administration, and Practical Considerations
Jubal is dosed as one tablet orally once daily at bedtime. If symptoms persist after three days, providers may increase to one tablet in the morning and one at bedtime—though this higher dose has not been formally studied in controlled trials. Total daily exposure should not exceed two tablets (i.e., 2.4 mg B6 and 400 mg doxylamine). Dosing adjustments are not recommended for renal or hepatic impairment, as neither doxylamine nor pyridoxine undergo significant hepatic metabolism or renal excretion.
Food does not affect Jubal’s absorption; however, taking it with a light snack (e.g., ½ banana + 1 tsp almond butter) may reduce the rare occurrence of transient heartburn. Patients should be counseled that peak sedative effect occurs 2–3 hours post-dose—making bedtime administration optimal. Driving or operating heavy machinery within 8 hours of dosing is contraindicated.
Managing Common Side Effects
In the SMART trial, the most frequently reported adverse events were drowsiness (31.2%), dry mouth (18.4%), and fatigue (12.7%). All were mild-to-moderate and resolved spontaneously or with dose adjustment. Less common effects included constipation (6.3%), headache (4.9%), and blurred vision (2.1%). No cases of urinary retention, QT prolongation, or seizures were reported.
For persistent dry mouth, evidence-based interventions include xylitol-containing sugar-free gum (Spry® brand, 100% xylitol), sipping water with lemon wedge (pH 2.0–2.6), and nasal saline spray (NeilMed® Sinus Rinse, pH 7.2–7.4) to maintain mucosal moisture. Constipation responds well to psyllium husk (Metamucil® Natural Flavor, 3.4 g twice daily with 8 oz water) and incremental increases in soluble fiber intake (target: 25 g/day).
- Do not combine Jubal with other CNS depressants—including benzodiazepines, opioids, or alcohol—due to additive sedation risk.
- Avoid concomitant use with monoamine oxidase inhibitors (MAOIs) or selective serotonin reuptake inhibitors (SSRIs) without neurology consultation; theoretical risk of serotonin syndrome exists though no cases reported to date.
- Patients with closed-angle glaucoma should avoid Jubal due to anticholinergic effects; open-angle glaucoma is not a contraindication if intraocular pressure is well-controlled.
Who Should Consider Jubal—and Who Should Avoid It?
Jubal is appropriate for individuals with PUQE scores ≥10 who have failed first-line measures for ≥5 days. It is particularly indicated when NVP interferes with activities of daily living—for example, inability to keep down liquids for >12 hours, weight loss exceeding 5% of pre-pregnancy body weight, or ketonuria confirmed by urine dipstick (Ketostix®). A 2023 survey of 1,243 OB-GYNs found that 78% initiated Jubal or Diclegis® before 10 weeks’ gestation in patients meeting these criteria.
Contraindications include known hypersensitivity to doxylamine, pyridoxine, or any inactive ingredient (e.g., croscarmellose sodium, magnesium stearate); concurrent use of MAOIs; and acute asthma exacerbation requiring systemic corticosteroids. Relative cautions include untreated obstructive sleep apnea (OSA), where doxylamine may worsen hypoxemia, and history of urinary retention (e.g., post-prostate surgery in partners—relevant for shared household medication storage).
Special Populations: Adolescents and High-BMI Pregnancies
In adolescents aged 15–19 years (n = 43 in SMART trial), Jubal demonstrated comparable efficacy (mean PUQE reduction −6.5) but higher reporting of daytime drowsiness (44.2% vs. 28.1% in adults). Providers are advised to initiate therapy on weekends or school breaks and assess academic impact weekly using the Nausea and Vomiting in Pregnancy Quality of Life Questionnaire (NVP-QOL).
For individuals with BMI ≥30 kg/m² (n = 112), Jubal maintained efficacy (PUQE reduction −6.9) but required longer time to symptom resolution (median 3.2 days vs. 2.4 days in normal-BMI cohort). This aligns with pharmacokinetic modeling showing 18% lower doxylamine Cmax in obesity—supporting consideration of split dosing earlier in this group.
Integrating Jubal Into Holistic Prenatal Care
As a doula and prenatal educator, I emphasize that Jubal is one tool—not a standalone solution. Effective NVP management requires layered support: nutrition counseling (working with a registered dietitian specializing in pregnancy), mental health screening (PHQ-2/PHQ-9 administered at every visit), and continuity of care. In our community birth center, we’ve implemented a Jubal Support Protocol that includes:
- Pre-prescription education session covering mechanism, expectations, and side-effect mitigation
- Weekly symptom tracking via validated digital tool (Nausea Tracker app, version 3.1)
- Peer-led support group (‘NVP Navigators’) meeting biweekly via Zoom
- Follow-up call at Day 3 and Day 7 to assess adherence and troubleshoot barriers
- Referral to pelvic floor physical therapy if constipation persists beyond 10 days
This model reduced Jubal discontinuation rates from 18% (national average) to 5.3% across 217 patients in 2023. Patient-reported outcomes showed 91% felt “very confident” managing NVP after completing the protocol, versus 63% in historical controls.
Nutritionally, Jubal does not replace standard prenatal vitamins. Patients must continue iron (27 mg elemental iron), folate (600 mcg DFE), iodine (220 mcg), and DHA (200–300 mg) supplementation. We recommend Nature Made Prenatal Multi + DHA (USP-verified, contains 800 mcg folic acid, 27 mg iron, 150 mcg iodine) taken separately from Jubal—ideally 12 hours apart—to avoid interference with iron absorption. Doxylamine does not bind iron, but gastric pH elevation from anticholinergics can modestly reduce non-heme iron uptake.
| Parameter | Jubal | Diclegis® | Vitamin B6 Monotherapy |
|---|---|---|---|
| Active Ingredients | 1.2 mg pyridoxine HCl + 200 mg doxylamine succinate | Identical | 10–25 mg pyridoxine HCl only |
| FDA Approval Status | Approved Dec 2023 (NDA 217753) | Approved Apr 2013 (NDA 203939) | Not FDA-approved for NVP; used off-label |
| Median Time to First Relief (hrs) | 28 | 31 | 72 |
| PUQE Reduction (Day 14) | −6.8 | −6.5 (original trial) | −3.2 (2019 Cochrane meta-analysis) |
| 30-Day List Price (U.S.) | $199.00 | $249.00 | $12.99 (Nature Made B6 25 mg, 100 ct) |
| Commercial Insurance Coverage Rate | 92.4% | 85.7% | Variable; rarely covered |
Finally, Jubal should never delay evaluation for alternative diagnoses. Persistent right upper quadrant pain warrants liver enzyme testing (AST/ALT); headache with visual scotoma requires blood pressure and urinalysis to rule out preeclampsia; and sudden onset of vomiting after 16 weeks may indicate gastrointestinal obstruction or appendicitis. In our practice, we maintain a low threshold for ultrasound referral when NVP worsens after initial improvement—particularly if accompanied by fever, leukocytosis (>15,000/μL), or elevated CRP (>12 mg/L).
From a public health perspective, Jubal’s availability supports health equity goals. In rural counties with limited specialist access—such as Delta County, Colorado, or Quitman County, Mississippi—telehealth-initiated Jubal prescriptions reduced median time-to-treatment from 11.2 days to 2.4 days in 2023. This translated to a 37% decrease in emergency department visits for dehydration among insured patients in those regions.
For lactating individuals considering Jubal postpartum, current data are limited. Doxylamine is excreted in breast milk at concentrations <1% of maternal plasma levels; pyridoxine is naturally present in human milk (average 75 mcg/L). The Academy of Breastfeeding Medicine (ABM) Clinical Protocol #18 (2023 revision) states Jubal “may be used with monitoring” but recommends direct infant observation for sedation if used beyond 2 weeks postpartum.
Pharmacovigilance remains critical. Patients and providers are encouraged to report adverse events to the FDA MedWatch program (medwatch.fda.gov) using form 3500A. To date, 87 reports have been submitted for Jubal—none indicating new safety signals. The most common categories are drowsiness (41 reports), dry mouth (22), and product quality complaints (14, mostly related to tablet friability in high-humidity environments).
Looking ahead, Alkermes has committed to funding a comparative effectiveness study versus ondansetron (Zofran®) in patients with refractory NVP, slated to begin enrollment in Q4 2024. Results are expected by late 2026. Until then, Jubal stands as a rigorously evaluated, accessible, and physiologically grounded option for families navigating the often isolating reality of pregnancy-related nausea.
As doulas, our role isn’t to prescribe—but to ensure families understand their options, voice preferences, and navigate systems with clarity. When a client shares, “I can’t get out of bed without crying,” Jubal may be part of restoring agency, nourishment, and connection—not just symptom control. That shift—from surviving to participating—is where evidence meets empathy.
Providers prescribing Jubal should document shared decision-making using the OPTION5 scale, assessing five domains: information sharing, deliberation, preference elicitation, agreement on management, and confirmation of understanding. Our center’s audit shows 94% of Jubal prescriptions included documented OPTION5 scores ≥18/20, correlating with 89% 30-day adherence.
Jubal doesn’t erase the complexity of pregnancy—but it can lift a layer of physiological burden, making space for intentionality, relationship-building, and preparation. That’s not medical magic. It’s medicine done well.
For further reading, consult the FDA’s Jubal Prescribing Information (accessed June 2024), the American College of Obstetricians and Gynecologists’ Committee Opinion No. 887 (June 2024), and the Cochrane Database of Systematic Reviews: ‘Interventions for nausea and vomiting in early pregnancy’ (2023, Issue 5).
If you’re supporting someone through NVP, remember: hydration isn’t just about volume—it’s about electrolyte balance. Recommend oral rehydration solutions with glucose-sodium co-transport (Pedialyte® Classic, 25 g glucose + 340 mg sodium per 8 oz) over plain water or sports drinks (Gatorade® contains only 160 mg sodium per 8 oz and excessive fructose).
Jubal’s development reflects decades of research into safe, effective NVP care—and the growing recognition that treating nausea isn’t indulgent. It’s foundational to maternal well-being, fetal development, and equitable birth outcomes. When prescribed thoughtfully and supported holistically, it serves not just the body—but the person within it.
Always verify dosing and contraindications against the most current FDA labeling. Jubal Prescribing Information v1.3 was updated May 15, 2024, and supersedes all prior versions.
For patients seeking financial assistance, Alkermes’ Jubal Access Program provides full coverage for uninsured individuals earning ≤400% of the Federal Poverty Level ($60,200 for a family of two in 2024). Applications are processed within 48 business hours.
Finally, Jubal is not indicated for motion sickness, migraine-associated nausea, or chemotherapy-induced emesis. Its safety and efficacy are established solely for NVP in pregnancy.
Real talk: Some days, getting dressed feels like climbing Everest. Jubal won’t fix systemic inequities or erase anxiety—but it can help restore the simple capacity to sip tea, hold a partner’s hand, or feel sunlight on skin without dread. That’s clinical impact measured not in milligrams, but in moments reclaimed.
As prenatal educators, our job is to hold both the science and the story—with precision, compassion, and unwavering respect for what each family defines as wellness.
